Foghorn Therapeutics Inc. (FHTX) is a clinical-stage biopharmaceutical company developing precision medicines that target the chromatin regulatory system. The company's analyst coverage was substantially reset in early October 2026 after it and partner Eli Lilly (LLY) decided not to advance the SMARCA2 inhibitor FHD-909 into clinical expansion.
Five verifiable, current analyst price targets were collected. Guggenheim, H.C. Wainwright, and Stifel each maintained Buy ratings with $5.00 targets (dated October 1–2, 2026), while Evercore ISI moved to In Line with a $3.00 target (October 13, 2026) and Wedbush moved to Neutral with a $2.00 target (October 2, 2026). The arithmetic mean of these five targets is $4.00, with an approximate range of $2.00 to $5.00.
The wide range reflects a genuine split: the $5.00 bulls value the remaining wholly owned pipeline — including a selective EP300 degrader, an oral inflammation and immunology program, and a selective CBP degrader — as multiple "shots on goal." The more cautious firms emphasize the loss of the lead clinical opportunity, early-stage risk, and a leaner catalyst calendar. Notably, several firms (BTIG, TD Cowen, and Citizens) downgraded to Hold without publishing new price targets, signaling a retreat to the sidelines rather than outright bearishness.
With shares trading near $2.05 and a market capitalization of roughly $122 million, the stock sits near its 52-week low of $1.79 and far below its 52-week high of $7.61. Reaching $4.00 implies upside of approximately 95%, which must be characterized as a very large move. It would not fully retrace the stock's 2026 decline but would represent a near-doubling from current levels.
The path would depend on converting preclinical promise into clinical proof. Management has redirected resources toward wholly owned programs after a 40% workforce reduction and organizational restructuring, extending the projected cash runway into the second half of 2029. That balance-sheet cushion removes near-term financing pressure but does not, by itself, create value; investors would need to see concrete progress, such as nomination of a development candidate or movement toward clinical trials for the EP300 degrader or related programs.
Several factors could support a recovery. First, the extended cash runway into late 2029 reduces immediate dilution risk and gives management time to advance earlier-stage assets. Second, the platform retains multiple independent programs, so validation in any one area — heme malignancies, oncology, or immunology — could re-rate the stock. Third, the shares now trade near net cash in some assessments, which can limit downside and attract value-oriented and event-driven buyers. Finally, new partnerships or licensing deals on the wholly owned programs would provide both nondilutive capital and external validation, a catalyst that analysts across the bull-bear divide have flagged as important.
The principal obstacle is the loss of FHD-909, which had been the company's lead clinical opportunity. With that program and the SMARCA2 degrader set aside, and the Eli Lilly collaboration effectively ended, the near-term catalyst calendar is thin until roughly 2028, according to Street commentary. Remaining programs are preclinical or early-stage, carrying the usual risks of failure, delay, or deprioritization. Downgrades from Wedbush, Evercore ISI, BTIG, TD Cowen, and Citizens reflect a more cautious consensus that the stock may need new data or new partnerships to re-rate. Execution risk after a 40% workforce reduction is another consideration.
The stock's market structure has deteriorated sharply in 2026, with the price collapsing from above $7 to near $2. The $1.79 52-week low is the key support level to watch, with the round $2.00 level acting as a psychological and technical floor that has held in recent sessions. On the upside, $3.00 (Evercore ISI's target) represents an initial resistance zone, followed by the $5.00 area, which coincides with three of the five analyst targets and the former trading range's upper boundary. The roughly 95% move required to reach $4.00 implies clearing multiple resistance layers, not a single breakout.
Analyst price targets typically reflect a research horizon of about 12 months, though individual assumptions vary and no official horizon was disclosed for all five targets. Key items to monitor include the next earnings report, expected in early November 2026, and management's commentary on cash runway, restructuring execution, and pipeline prioritization. Beyond that, watch for development-candidate nominations, clinical-trial initiations, any new partnership or licensing announcements, and further analyst revisions, given how quickly the target range reset after the FHD-909 decision.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-dependent name like FHTX, such tools can help traders track shifting momentum and technical posture alongside the fundamental story. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently.
The question of whether Foghorn Therapeutics can reach $4.00 is not a binary call but a judgment about how the market will weigh remaining pipeline optionality against the loss of its lead asset. The $4.00 central target — the average of five verified analyst targets ranging from $2.00 to $5.00 — requires a roughly 95% advance from about $2.05, a very large move that is not imminent under current conditions. Support comes from an extended cash runway, multiple early-stage programs, and a valuation near net cash; the obstacles are a thin catalyst calendar, execution risk, and genuine analyst disagreement. Investors should monitor pipeline progress, potential new partnerships, and analyst revisions before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with ARVN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To FHTX | 1D Price Change % | ||
|---|---|---|---|---|
| FHTX | 100% | -6.86% | ||
| ARVN - FHTX | 42% Loosely correlated | +2.37% | ||
| IMTX - FHTX | 39% Loosely correlated | -0.16% | ||
| IMVT - FHTX | 39% Loosely correlated | +1.59% | ||
| DNLI - FHTX | 38% Loosely correlated | -2.36% | ||
| AXON - FHTX | 38% Loosely correlated | -0.21% | ||
More | ||||